Denali Therapeutics Inc.
DNLI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001714899
In the last 90 days, Denali Therapeutics Inc. insiders filed 0 open-market purchases and 4 sales; 294 institutions reported holding it in 13F filings for Q2 2026, worth $4.46B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $435.3K in total
- 4
- 13F holdersQ2 2026, +28 vs. previous quarter
- 294
- 13F valueReported value at the end of Q2 2026
- $4.46B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding DNLI, Q2 2026
No superinvestor reported holding DNLI at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Denali Therapeutics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 9, 2026 (view filing)4:44 PM ET | Sep 4 | 5 days | Chin Peter ScottChief Medical Officer | SSale | −1.65K | $22.29 | −$36.9K | −0.8%204.5K after | |
| Sep 4, 2026 (view filing)5:02 PM ET | Sep 2 | 2 days | Thornberry NancyDirector | SSale | −11.4K | $22.90 | −$261.9K | −36.8%19.7K after | 2 lots10b5-1 |
| Sep 3, 2026 (view filing)4:17 PM ET | Sep 1 | 2 days | Schuth Alexander O.COFO and Secretary | SSale | −2.77K | $23.44 | −$64.9K | −1.0%279.0K after | 10b5-1 |
| Aug 13, 2026 (view filing)5:01 PM ET | Aug 11 | 2 days | Schuth Alexander O.COFO and Secretary | SSale | −2.86K | $25.07 | −$71.6K | −1.0%281.8K after | |
| Jan 8, 2026 (view filing) | Jan 6 | 2 days | Schuth Alexander O.COFO and Secretary | SSale | −17.2K | $16.50 | −$284.1K | −5.7%282.8K after | |
| Jan 8, 2026 (view filing) | Jan 6 | 2 days | Watts Ryan J.President and CEO | SSale | −35.2K | $16.50 | −$580.8K | −10.6%296.8K after | |
| Dec 15, 2025 (view filing)4:33 PM ET | Dec 11 | 4 days | Baker Julian and 5 othersDirector | PPurchase | +2.29M | $17.49 | +$40.0M | –26.0M after | Derivative2 lots |
| Aug 14, 2025 (view filing) | Aug 12 | 2 days | Schuth Alexander O.COFO and Secretary | SSale | −2.94K | $13.58 | −$39.9K | −1.2%242.3K after | |
| Aug 14, 2025 (view filing) | Aug 12-13 | 2 days | Ho CaroleChief Medical Officer | SSale | −3.74K | $13.81 | −$51.7K | −1.7%216.6K after | 2 lots10b5-1 |
| Jul 11, 2025 (view filing) | Jul 9 | 2 days | Watts Ryan J.President and CEO | SSale | −495.3K | $15.00 | −$7.43M | −66.2%253.1K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Denali Therapeutics Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Banque Cantonale Vaudoise | 17,926 | $461.0M | 0.06% | +17,926 | New |
| T. Rowe Price Investment Management, Inc. | 16,178,963 | $416.1M | 0.27% | +7,659,771+89.9% | Added |
| BlackRock, Inc. | 14,026,413 | $360.8M | 0.01% | +991,979+7.6% | Added |
| Baillie Gifford & Co | 11,960,230 | $307.6M | 0.28% | −106,249−0.9% | Reduced |
| State Street Corp | 7,049,304 | $181.3M | 0.01% | +777,303+12.4% | Added |
| Temasek Holdings (Private) Ltd | 7,012,974 | $180.4M | 0.49% | 00.0% | Unchanged |
| Vanguard Portfolio Management LLC | 6,477,057 | $166.6M | 0.01% | +356,897+5.8% | Added |
| Vanguard Capital Management LLC | 6,275,729 | $161.4M | 0.00% | +127,772+2.1% | Added |
| FMR LLC | 4,535,836 | $116.7M | 0.01% | −39,538−0.9% | Reduced |
| Goldman Sachs Group Inc | 4,155,895 | $106.9M | 0.01% | −251,360−5.7% | Reduced |